Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case–control study

Klara Rosta, Johannes Ott, Fanni Kelemen, Wilhelm Temsch, Tobias Lahner, Theresa Reischer, Hanns Helmer, A. Somogyi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To determine the incidence of gestational diabetes mellitus (GDM) in pregnant women who received vaginal progesterone due to short cervical length or to prevent recurrent preterm birth. Methods: In this retrospective study, we included 190 women with singleton pregnancies at risk for preterm birth who received vaginal natural progesterone (200 mg daily between gestational weeks 16 + 0 and 36 + 0) for a minimum of 4 weeks and delivered > 28 weeks. The control group consisted of 242 age- and body mass index (BMI)-matched patients without progesterone administration. Data were acquired from a database containing prospectively collected information. Patients with pre-existing diabetes, and conception after in vitro fertilisation procedure were excluded. Results: The incidence of GDM did not differ significantly between the progesterone-treated and the control group (14.7% vs. 16.9%, respectively; p = 0.597). In a binary regression model, patients with higher pre-pregnancy BMI (OR 1.1; p = 0.006), and those with a family history of diabetes had a higher risk for GDM development (OR 1.8; p = 0.040), whereas vaginal progesterone treatment had no significant influence (p = 0.580). Conclusion: The use of vaginal progesterone for the prevention of recurrent preterm delivery and in women with a short cervix does not seem to be associated with an increased risk of GDM.

Original languageEnglish
JournalArchives of Gynecology and Obstetrics
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Gestational Diabetes
Progesterone
Retrospective Studies
Premature Birth
Body Mass Index
Therapeutics
Pregnancy
Control Groups
Incidence
Fertilization in Vitro
Cervix Uteri
Pregnant Women
Databases

Keywords

  • Gestational diabetes mellitus
  • High-risk pregnancy
  • Pregnancy
  • Prenatal care
  • Preterm birth

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case–control study. / Rosta, Klara; Ott, Johannes; Kelemen, Fanni; Temsch, Wilhelm; Lahner, Tobias; Reischer, Theresa; Helmer, Hanns; Somogyi, A.

In: Archives of Gynecology and Obstetrics, 01.01.2018.

Research output: Contribution to journalArticle

Rosta, Klara ; Ott, Johannes ; Kelemen, Fanni ; Temsch, Wilhelm ; Lahner, Tobias ; Reischer, Theresa ; Helmer, Hanns ; Somogyi, A. / Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case–control study. In: Archives of Gynecology and Obstetrics. 2018.
@article{7953a8669b5e42c3a58f1fb3d2d2b0d0,
title = "Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case–control study",
abstract = "Purpose: To determine the incidence of gestational diabetes mellitus (GDM) in pregnant women who received vaginal progesterone due to short cervical length or to prevent recurrent preterm birth. Methods: In this retrospective study, we included 190 women with singleton pregnancies at risk for preterm birth who received vaginal natural progesterone (200 mg daily between gestational weeks 16 + 0 and 36 + 0) for a minimum of 4 weeks and delivered > 28 weeks. The control group consisted of 242 age- and body mass index (BMI)-matched patients without progesterone administration. Data were acquired from a database containing prospectively collected information. Patients with pre-existing diabetes, and conception after in vitro fertilisation procedure were excluded. Results: The incidence of GDM did not differ significantly between the progesterone-treated and the control group (14.7{\%} vs. 16.9{\%}, respectively; p = 0.597). In a binary regression model, patients with higher pre-pregnancy BMI (OR 1.1; p = 0.006), and those with a family history of diabetes had a higher risk for GDM development (OR 1.8; p = 0.040), whereas vaginal progesterone treatment had no significant influence (p = 0.580). Conclusion: The use of vaginal progesterone for the prevention of recurrent preterm delivery and in women with a short cervix does not seem to be associated with an increased risk of GDM.",
keywords = "Gestational diabetes mellitus, High-risk pregnancy, Pregnancy, Prenatal care, Preterm birth",
author = "Klara Rosta and Johannes Ott and Fanni Kelemen and Wilhelm Temsch and Tobias Lahner and Theresa Reischer and Hanns Helmer and A. Somogyi",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00404-018-4895-1",
language = "English",
journal = "Archiv fur Gynakologie",
issn = "0932-0067",
publisher = "J.F. Bergmann",

}

TY - JOUR

T1 - Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case–control study

AU - Rosta, Klara

AU - Ott, Johannes

AU - Kelemen, Fanni

AU - Temsch, Wilhelm

AU - Lahner, Tobias

AU - Reischer, Theresa

AU - Helmer, Hanns

AU - Somogyi, A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To determine the incidence of gestational diabetes mellitus (GDM) in pregnant women who received vaginal progesterone due to short cervical length or to prevent recurrent preterm birth. Methods: In this retrospective study, we included 190 women with singleton pregnancies at risk for preterm birth who received vaginal natural progesterone (200 mg daily between gestational weeks 16 + 0 and 36 + 0) for a minimum of 4 weeks and delivered > 28 weeks. The control group consisted of 242 age- and body mass index (BMI)-matched patients without progesterone administration. Data were acquired from a database containing prospectively collected information. Patients with pre-existing diabetes, and conception after in vitro fertilisation procedure were excluded. Results: The incidence of GDM did not differ significantly between the progesterone-treated and the control group (14.7% vs. 16.9%, respectively; p = 0.597). In a binary regression model, patients with higher pre-pregnancy BMI (OR 1.1; p = 0.006), and those with a family history of diabetes had a higher risk for GDM development (OR 1.8; p = 0.040), whereas vaginal progesterone treatment had no significant influence (p = 0.580). Conclusion: The use of vaginal progesterone for the prevention of recurrent preterm delivery and in women with a short cervix does not seem to be associated with an increased risk of GDM.

AB - Purpose: To determine the incidence of gestational diabetes mellitus (GDM) in pregnant women who received vaginal progesterone due to short cervical length or to prevent recurrent preterm birth. Methods: In this retrospective study, we included 190 women with singleton pregnancies at risk for preterm birth who received vaginal natural progesterone (200 mg daily between gestational weeks 16 + 0 and 36 + 0) for a minimum of 4 weeks and delivered > 28 weeks. The control group consisted of 242 age- and body mass index (BMI)-matched patients without progesterone administration. Data were acquired from a database containing prospectively collected information. Patients with pre-existing diabetes, and conception after in vitro fertilisation procedure were excluded. Results: The incidence of GDM did not differ significantly between the progesterone-treated and the control group (14.7% vs. 16.9%, respectively; p = 0.597). In a binary regression model, patients with higher pre-pregnancy BMI (OR 1.1; p = 0.006), and those with a family history of diabetes had a higher risk for GDM development (OR 1.8; p = 0.040), whereas vaginal progesterone treatment had no significant influence (p = 0.580). Conclusion: The use of vaginal progesterone for the prevention of recurrent preterm delivery and in women with a short cervix does not seem to be associated with an increased risk of GDM.

KW - Gestational diabetes mellitus

KW - High-risk pregnancy

KW - Pregnancy

KW - Prenatal care

KW - Preterm birth

UR - http://www.scopus.com/inward/record.url?scp=85053513280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053513280&partnerID=8YFLogxK

U2 - 10.1007/s00404-018-4895-1

DO - 10.1007/s00404-018-4895-1

M3 - Article

JO - Archiv fur Gynakologie

JF - Archiv fur Gynakologie

SN - 0932-0067

ER -